• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ZimVie Inc.

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email
    SC 13G 1 o114246sc13g.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.) *

     

    ZIMVIE Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    98888T107

    (CUSIP Number)

     

    Kamran Moghtaderi, Eversept Partners, L.P., 444 Madison Avenue, 22nd Floor, New York, NY 10022, 212-271-4211

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       
     

     

    CUSIP No. 98888T107   13G   Page 2 of 9 Pages
             

             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Eversept Partners, L.P.

    47-5115829

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

      5.   SOLE VOTING POWER
     
    1,928,493
      6.   SHARED VOTING POWER
     
    142,287*
      7.   SOLE DISPOSITIVE POWER
     
    1,928,493
      8.   SHARED DISPOSITIVE POWER
     
    142,287*

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,070,780
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%**
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       

     

    *See Item 4 of the Schedule 13G

     

       
     

     

    CUSIP No. 98888T107   13G   Page 3 of 9 Pages
             

             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Eversept 1 LLC

    81-4423039

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

      5.   SOLE VOTING POWER
     
    1,928,493
      6.   SHARED VOTING POWER
     
    142,287*
      7.   SOLE DISPOSITIVE POWER
     
    1,928,493
      8.   SHARED DISPOSITIVE POWER
     
    142,287*

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,070,780
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%**
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    HC
       

     

    *See Item 4 of the Schedule 13G

     

       
     

     

    CUSIP No. 98888T107   13G   Page 4 of 9 Pages
             

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Kamran Moghtaderi
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

      5.   SOLE VOTING POWER
     
    1,928,493
      6.   SHARED VOTING POWER
     
    142,287*
      7.   SOLE DISPOSITIVE POWER
     
    1,928,493
      8.   SHARED DISPOSITIVE POWER
     
    142,287*

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,070,780
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.5%**
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN, HC
       

     

    *See Item 4 of the Schedule 13G

     

       
     

     

    CUSIP No. 98888T107   13G   Page 5 of 9 Pages
             

     

    Item 1.

     

      (a) Name of Issuer
    ZIMVIE Inc.
         
      (b)

    Address of Issuer’s Principal Executive Offices
    4555 Riverside Drive

    Palm Beach Gardens, FL 33410

         

     

    Item 2.

     

      (a)

    Name of Person Filing


    This statement is jointly filed by and on behalf of Eversept Partners, L.P., a Delaware limited partnership (the “Investment Manager”), Eversept 1 LLC, a Delaware limited liability company (the “IM GP”) and Kamran Moghtaderi (collectively referred herein as “Reporting Persons”). The Investment Manager is the investment manager of advisory clients, and may be deemed to indirectly beneficially own securities owned by its advisory clients. The IM GP is the general partner of the Investment Manager and may be deemed to indirectly beneficially own securities owned by the Investment Manager. Mr. Moghtaderi is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, the IM GP. Eversept’s advisory clients are the record and direct beneficial owners of the securities covered by this statement.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.

         
      (b) Address of the Principal Office or, if none, residence
    The address of the principal business office of each of the Reporting Persons is c/o Eversept Partners, L.P., 444 Madison Avenue, 22nd Floor, New York, NY 10022.
         
      (c) Citizenship
    See Item 4 on the cover page hereto.
         
      (d) Title of Class of Securities
    Common Stock, par value $0.01 per share
         
      (e) CUSIP Number
    98888T107

     

       
     

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

     

    Item 4.  Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:  2,070,780
             
      (b)   Percent of class: 7.5%** 
             
      (c)   Number of shares as to which the person has:  
             
          (i) Sole power to vote or to direct the vote 1,928,493
             
          (ii) Shared power to vote or to direct the vote 142,287*
             
          (iii) Sole power to dispose or to direct the disposition of 1,928,493
             
          (iv)

    Shared power to dispose or to direct the disposition of 142,287*

     

    * Note: As of the close of business on September 30, 2024, Eversept and its controlling persons beneficially owned 2,070,780 Shares, including 142,287 Shares held in Eversept’s Managed Accounts.

    ** Note: As of September 30, 2024, Eversept and its controlling persons were the beneficial owners of approximately 7.5% of the outstanding Shares, based on 27,598,871 shares of Common Stock of the Issuer outstanding as of October 25, 2024, as reported in the Issuer’s Form 10-Q filed on October 30, 2024, including 0.5% of the outstanding Shares held in Eversept’s Managed Accounts.

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨.

     

    Instruction. Dissolution of a group requires a response to this item.

     

       
     

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable. 

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.  Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.  Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.  Certification.

     

          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
             
         

    Exhibits

     

    Exhibit A - Joint Filing Agreement

     

     

       
     

     

    CUSIP No. 98888T107   13G   Page 8 of 9 Pages
             

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

      November 14, 2024
      Date
         
         
         
      EVERSEPT PARTNERS, L.P.
         
      By: /s/ Kamran Moghtaderi  
      Managing Principal
         
      EVERSEPT 1 LLC
         
      By: /s/ Kamran Moghtaderi  
      Managing Member
         
      KAMRAN MOGHTADERI
         
      /s/ Kamran Moghtaderi  

     

       
     

     

    Exhibit A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, each of the undersigned hereby constitutes and appoints Eversept Partners, L.P., a Delaware limited partnership, as its true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

        Date: November 14, 2024
       
    EVERSEPT PARTNERS, L.P.  
         
    By: /s/ Kamran Moghtaderi    
    Managing Principal  
         
         
    EVERSEPT 1 LLC  
         
    By: /s/ Kamran Moghtaderi    
    Managing Member  
         
    KAMRAN MOGHTADERI  
         
    /s/ Kamran Moghtaderi    

     

     

     

     

     

     

    Get the next $ZIMV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    7/31/2025$19.00Buy → Neutral
    B. Riley Securities
    7/22/2025$19.00Underweight → Equal Weight
    Barclays
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    More analyst ratings

    $ZIMV
    SEC Filings

    View All

    SEC Form PREM14A filed by ZimVie Inc.

    PREM14A - ZimVie Inc. (0001876588) (Filer)

    8/15/25 5:02:32 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.

    SCHEDULE 13G/A - ZimVie Inc. (0001876588) (Subject)

    8/14/25 9:11:30 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by ZimVie Inc.

    DEFA14A - ZimVie Inc. (0001876588) (Filer)

    7/30/25 4:15:04 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Kanaglekar Indraneel covered exercise/tax liability with 145 shares, decreasing direct ownership by 0.23% to 62,851 units (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    7/3/25 4:17:15 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Kuntz Richard

    4 - ZimVie Inc. (0001876588) (Issuer)

    7/2/25 4:36:01 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Schneider Sandra converted options into 11,127 shares and covered exercise/tax liability with 2,710 shares, increasing direct ownership by 26% to 40,794 units (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    5/19/25 4:18:13 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ZimVie downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded ZimVie from Buy to Neutral and set a new price target of $19.00

    7/31/25 7:17:57 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie upgraded by Barclays with a new price target

    Barclays upgraded ZimVie from Underweight to Equal Weight and set a new price target of $19.00

    7/22/25 10:21:16 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on ZimVie with a new price target

    B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

    4/10/25 12:44:28 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025

    PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie's entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED") for $19.00 in cash per share. A copy of that press release is accessible by visiting the "Investor Relations" section of ZimVie's website. The transaction is expected to close by year-end 2025, su

    7/25/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China

    PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd. ("Osstem Implant"), a leading dental solutions provider specializing in high-quality implants and integrated dental technologies globally. The agreement expands ZimVie's global presence to further penetrate the large, growing Chinese implant market—estimated at greater than 10 million units annually1—and enhance customer access to its innovative implant portfolio. Osstem Implant is the market-leading provider of dental implants in China, with broad, established dis

    7/23/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    View All

    ZimVie Announces Upcoming Changes to Company's Board of Directors

    PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

    3/13/25 4:15:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    View All

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025

    PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie's entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED") for $19.00 in cash per share. A copy of that press release is accessible by visiting the "Investor Relations" section of ZimVie's website. The transaction is expected to close by year-end 2025, su

    7/25/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Reports First Quarter 2025 Financial Results

    Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

    5/8/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ZimVie Inc.

    SC 13G - ZimVie Inc. (0001876588) (Subject)

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    11/14/24 10:58:06 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    10/4/24 1:02:25 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care